Related Experiment Videos

Cardiac risk is not associated with hypertension treatment intensification

Jeremy B Sussman1, Donna M Zulman, Rodney Hayward

  • 1Veterans Affairs Center for Clinical Management Research, HSR&D Center of Excellence, Ann Harbor, MI, USA. jeremysu@med.umich.edu

The American Journal of Managed Care
|August 30, 2012
PubMed

Insights

Cardiovascular risk does not influence hypertension treatment intensification, despite its potential to prevent cardiac events. Integrating CV risk into treatment algorithms could improve care efficiency and outcomes.

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Clinical Decision-Making

Background:

  • Current hypertension guidelines often focus on individual risk factors rather than overall cardiovascular (CV) risk.
  • Considering comprehensive CV risk could enhance the efficiency and personalization of clinical care.

Purpose of the Study:

  • To investigate whether hypertension treatment intensification (TI) is more likely in patients with elevated CV risk.
  • To assess the impact of incorporating CV risk into treatment algorithms for hypertension management.

Main Methods:

  • A prospective cohort study involving 856 US veterans with diabetes and elevated blood pressure (BP).
  • Multilevel logistic regression was used to compare TI rates across three CV risk groups: history of heart disease, high-risk primary prevention (>20% 10-year risk), and low/medium risk (<20% 10-year risk).

Main Results:

  • No significant differences in TI rates were observed across the different CV risk groups.
  • Systolic BP, mean BP, and higher glycated hemoglobin levels were associated with increased TI, while home BP <140/90 mm Hg was linked to lower TI.
  • Models suggest that incorporating CV risk into TI decision algorithms could prevent an estimated 38% more cardiac events without increasing the number of treated patients.

Conclusions:

  • Overall CV risk does not appear to significantly influence clinical decisions regarding hypertension TI, although individual BP measurements do.
  • Adopting TI decision algorithms that integrate CV risk could significantly improve the efficiency and clinical utility of cardiovascular preventive care.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...